Astellas Receives Approval for a Supplemental New Drug Application for Irribow® Irribow® OD, a Treatment of Diarrhea-predominant Irritable Bowel Syndrome, in Japan Tokyo, May 26, Astellas Pharma Inc. (“Astella - Palonosetron - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2015-05-26 01:47:13 Antiemetics Abdominal pain General practice Syndromes Ketones Irritable bowel syndrome Diarrhea Ramosetron 5-HT3 antagonist Medicine Health Gastroenterology		Astellas Receives Approval for a Supplemental New Drug Application for Irribow®/Irribow® OD, a Treatment of Diarrhea-predominant Irritable Bowel Syndrome, in Japan Tokyo, May 26, Astellas Pharma Inc. (“Astella Add to Reading List Source URL: www.astellas.com Download Document from Source Website File Size: 73,81 KB Share Document on Facebook

	CMTF005 - Food is Medicine - Checklist_Debranded DocID: 1xVMk - View Document
	Pacemakers and Implantable Cardiac Defibrillators: Software Radio Attacks and Zero-Power Defenses Daniel Halperin† Thomas S. Heydt-Benjamin† DocID: 1xVge - View Document
	CMTF005 - Food is Medicine - Checklist_Debranded_with bleed DocID: 1xUza - View Document
	CMTF005 - Food is Medicine - Checklist_Debranded_edited DocID: 1xTtU - View Document
	PDF Document DocID: 1xSqy - View Document